1. Home
  2. MGF vs MGNX Comparison

MGF vs MGNX Comparison

Compare MGF & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MFS Government Markets Income Trust

MGF

MFS Government Markets Income Trust

HOLD

Current Price

$3.02

Market Cap

99.1M

Sector

Finance

ML Signal

HOLD

Logo MacroGenics Inc.

MGNX

MacroGenics Inc.

HOLD

Current Price

$1.78

Market Cap

115.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MGF
MGNX
Founded
1987
2000
Country
United States
United States
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
99.1M
115.8M
IPO Year
N/A
2013

Fundamental Metrics

Financial Performance
Metric
MGF
MGNX
Price
$3.02
$1.78
Analyst Decision
Hold
Analyst Count
0
5
Target Price
N/A
$3.20
AVG Volume (30 Days)
104.4K
955.6K
Earning Date
01-01-0001
03-19-2026
Dividend Yield
7.64%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$127,626,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.91
$0.99
52 Week High
$3.46
$3.00

Technical Indicators

Market Signals
Indicator
MGF
MGNX
Relative Strength Index (RSI) N/A 49.06
Support Level N/A $1.66
Resistance Level N/A $1.97
Average True Range (ATR) 0.00 0.12
MACD 0.00 -0.02
Stochastic Oscillator 0.00 29.58

Price Performance

Historical Comparison
MGF
MGNX

About MGF MFS Government Markets Income Trust

MFS Government Markets Income Trust is a United States-based diversified, closed-end management investment company. Its investment objective is to seek high current income. The fund invests a majority of the net assets, including borrowings for investment purposes, in U.S. and foreign government securities. The company invest various sectors like U.S. Treasury Securities, Mortgage-Backed Securities, Investment Grade Corporates, Municipal Bonds, Non-U.S. Government Bonds, etc, out of which maximum revenue is gained from U.S. Treasury Securities.

About MGNX MacroGenics Inc.

Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.

Share on Social Networks: